Coronary interventions Drug-coated Balloons for the Treatment of Coronary In-stent Restenosis: A Multicentre, Randomised Controlled Clinical Study Hamm C, Dorr O, Wöhrle J, Krachhardt F, Ince H, Zeus T, Berland J, Piot C, Roubille F, Schult I, Allocco D, Nef H November 20, 2019 | 10.4244/EIJ-D-19-00051
Coronary interventions Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial Serruys P, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Edes I, van der Harst P, Krachhardt F, Thijssen J, Rademaker-Havinga T, Garg S, Steg P, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F March 17, 2019 | 10.4244/EIJ-D-19-00202
New issue Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue (Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right)) December 6, 2019
Trials Book Discover 5 new trials: GALILEO, CONDI-2/ERIC-PCI, EVOLUTE II-5 years, SCOPE and Excel 5 years (The Trials book is supported by Biotronik) December 13, 2019
Editorial 2019 – A leap year for valvular heart disease (Course directors PCR London Valves 2019) November 15, 2019